期刊文献+

利塞膦酸钠对去势骨质疏松白兔的实验研究

Risedronate for osteoporosis in ovariectomized rabbits experimental study
下载PDF
导出
摘要 目的观察和分析利塞膦酸钠对去势骨质疏松白兔的治疗作用。方法观察利塞膦酸钠(2,5mg.kg-1.d-1)对实验性骨质疏松白兔血清碱性磷酸酶活性,血钙,血磷值,股骨骨密度及骨小梁宽度的影响。结果与对照组相比,利塞膦酸钠可明显增加去势所致骨质疏松白兔血清ALP、血钙值(P<0.01),股骨骨密度及骨小梁宽度的测定与对照组相比有显著差异(P<0.01),血磷值无明显差异(P>0.05)。结论利塞膦酸钠对去势所致骨质疏松白兔有明显的治疗作用。 Objective To obeserve and analyze of risedronate for osteoporosis inovariectomized rabbits therapeutic effect.Methods 21 rabbits were divided into 3 groups:contro group,OP and treated with risedronate at a low dose(2 mg·kg-1·d-1)and OP and treated with risedronate at a high dose(5mg·kg-1·d-1).OP was induced by ovariectomized.The studies were carried out to determine the effect of risedronate on serum ALP,serum calcium,BMD and bone trabeculae.Results Compared with the control group,risedronate significantly increased due to osteoporosis in ovariectomized rabbit serum ALP,serum calcium(P0.01),femoral bone mineral density and trabecular bone measured the width of the control group there were significant differences(P0.01),serum phosphorus value was no significant difference(P0.05).Conclusion The result of risedronate for osteoporosis in overiectomized rabbits have signifcant therapeutic effect.
作者 李蔚 张妍
机构地区 解放军第
出处 《颈腰痛杂志》 2011年第3期187-189,共3页 The Journal of Cervicodynia and Lumbodynia
关键词 利塞膦酸钠 骨质疏松 去势 risedronate osteoporosis castration
  • 相关文献

参考文献8

  • 1Carr AJ,Thompson PW,Cooper C.Factors assocated with adherence and persistence to bisphosphonate therapy in osteoporosis:a cross-sectionsurvey[J].Osteoporos Int,2006,17:1638-1644.
  • 2全会标,高勇义.利塞膦酸钠临床研究进展[J].医学综述,2007,13(1):66-68. 被引量:12
  • 3Mo ri H.M anabo M,Kurach i Y,et al.Oateo integration of dentalimplants in rabbit bone with lowm ineral density[J].J OralMaxillofac Surg,1997,55:351.
  • 4Wells GA,Cranny A,Peterson Jet al.Alendronate for the pri mary and secondary prevention of osteoporotic fractures in postmenopausa] women[J].Cochrane Syst Rev,2008,nr.I,CD:001155.
  • 5Fujimo to T,N iim i A,Saw ai T,et al.Effects of stero id2induced o steopo ro sis on o steo integrat ion of titanium imp lants[J].Int J Oral Maxillofac Impl,1998,13:183.
  • 6Glintborg D,Andersen M,Hagen C,et al.Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome:a ran domized,placebo-controlled trial[J].J Clin Endocrinol Metab,2008,93:1696-1701.
  • 7Cao JJ,Wronski TJ,Iwaniec U,et al.Aging increases stromal osteoblastic cell-induced oateoclastogenesis and alters the osteo clast precursor pool in the mouse[J].J Bone Miner Res,2005,20:1659-1668.
  • 8Glintborg D,Andersen M,Hagen C,et al.Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome:arandom ized,placebo-controlled trial[J].J Clin Endocrinol Metab,2008.93:1696-1701.

二级参考文献17

  • 1姚斌,许雯,李建娟,胡国亮,翁建平,梁奕铨,胡少眉.利塞膦酸钠在防治绝经后骨质疏松症中的作用[J].中华全科医师杂志,2004,3(4):241-244. 被引量:3
  • 2潘天荣,王长江,邵宜波,汪延华.二膦酸盐治疗骨质疏松及骨量减少的随机对照研究[J].中国骨质疏松杂志,2005,11(3):356-358. 被引量:3
  • 3Frith JC,Monkkonen J,Auriola S,et al.The molecular mechanism of action of the anteresorptive and antiinflammatory drug clodronate:Evidence for the formation in vivo of a matabolite that inhabits bone resorption and causes osteoclast and macrophage apoptosis[J].Arthritis Rheum,2001,44(9):2201-2210.
  • 4Olmos JM,De Vega T,Perera L,et al.Etidronate inhibits the production of IL-6 by Osteoblast-like cells[J].Methods Find Exp Clin Pharmacol,1999,21(8):519-522.
  • 5Harris ST,Watts NB,Genant HK,et al.Effects of risedronate treatment on vertebral and novertebral fractures in women with postmenopausal osteoporosis:a randomized controlled trial[J].JAMA,1999,282 (14):1344-1352.
  • 6Fogelman I,Ribot C,Smith R,et al.Risedronate reverses bone loss in postmenopausal women with low bone mass:results from a multinational,double-blind,placebo-controlled trial[J].J Clin Endocrinol Metab,2000,85(5):1895-1900.
  • 7Reginster J,Minne HW,Sorensen OH,et al.Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal ostecporosis[J].Osteoporosis Int,2000,11 (1):83-91.
  • 8Mitchell DY,Eusebio RA,sauo Gibson NA,et al.Dose proportional pharmacokinetics of rise dronate on single dose oral administration to healthy volunteers[J].J Clin Pharmacol,2000,40 (3):258-265.
  • 9Mitchell DY,Heise MA,Pallone KA,et al.The effect of dosing regimen on the pharmacokinetics of risedronate[J].Br J Clin Pharmacol,1999,48(4):536-542.
  • 10Mitchell DY,St Peter JV,Eusebio RA,et al.Effect of renal function on risedronate pharmacokinetics after a single oral dose[J].Br J Clin Pharmacol,2000,49(3):215-222.

共引文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部